Summary: GLP-1 receptor agonists are associated with an increased incidence of cholesterol gallstones, likely due to rapid weight loss and reduced gallbladder motility
Patients who discontinue the medication typically see a return of their baseline libido, though the timeline varies
They also significantly reduce phosphorylation of the ryanodine receptor (RyR) at the S2814 site and lower the risk of triggered activity and atrial arrhythmias by suppressing calcium leakage (153), thereby reflecting their antiarrhythmic properties
Degraded peptide may lead to a less potent drug without any visible sign of the problem
Reported complications in GLP-1 lawsuits include gastroparesis, bowel obstruction, ileus, cyclic vomiting syndrome, gallbladder disease, pulmonary aspiration during surgery, and non-arteritic anterior ischemic optic neuropathy (NAION), a rare optic nerve injury associated with sudden and potentially permanent vision loss
Victoza is the brand name for liraglutide, a GLP-1 receptor agonist